Advanced search
Publication Cover
Pharmacogenomics and Personalized Medicine Volume 12, 2019 - Issue
Submit an article Journal homepage
1,702
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects

Margarita N Dorofeeva1 Department of Social Expertise, Urgent and Outpatient Therapy, First Moscow State Medical University (Sechenov University), Ministry of Healthcare, Moscow, Russia
,
Evgenia V Shikh2 Department of Clinical Pharmacology and Propedeutics of Internal Diseases, First Moscow State Medical University (Sechenov University), Ministry of Healthcare, Moscow, Russia
,
Zhanna M Sizova1 Department of Social Expertise, Urgent and Outpatient Therapy, First Moscow State Medical University (Sechenov University), Ministry of Healthcare, Moscow, Russia
,
Alisa V Tarasenko3 Medicine of the Future, First Moscow State Medical University (Sechenov University), Ministry of Healthcare, Moscow, RussiaORCID Iconhttps://orcid.org/0000-0001-7332-3183
ORCID Icon,
Natalia P Denisenko4 Research Institute, Russian Medical Academy of Continuous Professional Education, Ministry of Healthcare, Moscow, Russia;5 Department of Clinical Pharmacology and Therapy, Russian Medical Academy of Continuous Professional Education, Ministry of Healthcare, Moscow, RussiaCorrespondence[email protected]
,
Valeriy V Smirnov6 Department of Pharmaceutical and Toxicological Chemistry, First Moscow State Medical University (Sechenov university), Ministry of Healthcare, Moscow, Russia;7 Laboratory of Clinical Pharmacology, National Research Centre - Institute of Immunology, Federal Medical Biological Agency, Moscow, Russia
,
Kristina A Ryzhikova4 Research Institute, Russian Medical Academy of Continuous Professional Education, Ministry of Healthcare, Moscow, RussiaORCID Iconhttps://orcid.org/0000-0003-3505-8520
ORCID Icon,
Zhannet A Sozaeva4 Research Institute, Russian Medical Academy of Continuous Professional Education, Ministry of Healthcare, Moscow, Russia
,
Elena A Grishina4 Research Institute, Russian Medical Academy of Continuous Professional Education, Ministry of Healthcare, Moscow, Russia
&
Dmitriy A Sychev5 Department of Clinical Pharmacology and Therapy, Russian Medical Academy of Continuous Professional Education, Ministry of Healthcare, Moscow, Russia
 show all
Pages 329-339 | Published online: 05 Nov 2019

References

  • McKeever RG, Hamilton RJ. Calcium channel blockers In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2019.
  • Bhatnagar V, Garcia EP, O’Connor DT, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010;31(2):95–103. doi:10.1159/00025868819907160
  • Kim K-A, Park P-W, Lee O-J, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther. 2006;80(6):646–656. doi:10.1016/j.clpt.2006.09.00917178265
  • Zhu Y, Wang F, Li Q, et al. Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014;42(2):245–249. doi:10.1124/dmd.113.05540024301608
  • Golan DE, Armstrong AW, Armstrong EJ. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Philadelphia: Wolters Kluwer; 2017.
  • Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37. doi:10.5009/gnl1550227840364
  • Dean L. Omeprazole Therapy and CYP2C19 Genotype In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
  • Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab Dispos. 2013;41(7):1414–1424. doi:10.1124/dmd.113.05172223620487
  • Li X-Q, Weidolf L, Simonsson R, Andersson TB. Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther. 2005;315(2):777–787. doi:10.1124/jpet.105.09092816093273
  • Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32:821–827. doi:10.1124/dmd.32.8.82115258107
  • Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos. 2012;40(40):1698–1711. doi:10.1124/dmd.112.04557522648560
  • Caraco Y, Wilkinson GR, Wood AJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther. 1996;60(4):396–404. doi:10.1016/S0009-9236(96)90196-48873687
  • Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics. 2005;15(5):365–369. doi:10.1097/01213011-200505000-0001315864139
  • Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–673. doi:10.1038/clpt.2011.3421412232
  • Harmsze AM, Robijns K, van Werkum JW, et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemost. 2010;103(5):920–925. doi:10.1160/TH09-08-051620352154
  • Seo K-D, Kim YD, Yoon Y-W, Kim J-Y, Lee K-Y. Antiplatelet effect of clopidogrel can be reduced by calcium-channel blockers. Yonsei Med J. 2014;55(3):683–688. doi:10.3349/ymj.2014.55.3.68324719135
  • Wang Z-Y, Chen M, Zhu L-L, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015;11:449–467. doi:10.2147/TCRM.S8043725848291
  • Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–323. doi:10.1038/clpt.2013.10523698643

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.